Medtronic plc (MDT)
7 Dividend Stocks to Beat Inflation
Historically, energy stocks have performed the best when inflation spikes.
Broad-Based MedSurg Growth Likely to Aid MDT's Q4 Performance
Medtronic's Q4 results may get a lift from broad MedSurg growth, strong Cardiovascular demand and continued momentum in Diabetes.
Can MDT Stock Gain From Its Planned Acquisition of SPR Therapeutics?
Medtronic eyes a $650 million acquisition of SPR, adding the FDA-cleared SPRINT PNS System to expand its chronic pain treatment offerings ahead of the fiscal 2027 closing.
Medtronic (MDT) Advances While Market Declines: Some Information for Investors
The latest trading day saw Medtronic (MDT) settling at $77.32, representing a +1.54% change from its previous close.
Surgical Robotics Meets AI: Intuitive Surgical, Medtronic, and Stryker Are the Sleeper Plays of the Healthcare Boom
Surgical robotics is quietly becoming an artificial intelligence story. Every robotic procedure generates structured video, kinematic, and outcomes data that platforms feed back into surgeon training, intraoperative guidance, and predictive analytics.
Medtronic (MDT) Stock Drops Despite Market Gains: Important Facts to Note
In the closing of the recent trading day, Medtronic (MDT) stood at $74.54, denoting a -2.11% move from the preceding trading day.
Is It Worth Investing in Medtronic (MDT) Based on Wall Street's Bullish Views?
When deciding whether to buy, sell, or hold a stock, investors often rely on analyst recommendations. Media reports about rating changes by these brokerage-firm-employed (or sell-side) analysts often influence a stock's price, but are they really important?
Medtronic (MDT) Stock Sinks As Market Gains: Here's Why
In the latest trading session, Medtronic (MDT) closed at $77.79, marking a -2.76% move from the previous day.
Medtronic (MDT) Declines More Than Market: Some Information for Investors
Medtronic (MDT) closed the most recent trading day at $78.3, moving 2.13% from the previous trading session.
Medtronic: Expectations Are Low And That's The Opportunity
Medtronic is a diversified MedTech company undergoing business simplification and cost improvements, with a focus on margin recovery over high growth. MDT trades at a discount to peers, reflecting lower growth expectations, but current levels offer a reasonable entry into a stable, cash-generative business. Margin improvement, especially through the diabetes business separation and streamlined operations, is the key catalyst for potential re-rating and upside.
Advisors Capital Management LLC Has $43.69 Million Stake in Medtronic PLC $MDT
Advisors Capital Management LLC grew its holdings in Medtronic PLC (NYSE: MDT) by 4.5% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 454,855 shares of the medical technology company's stock after purchasing an additional 19,479 shares during the period. Advisors Capital
Medtronic: Is This Dividend Aristocrat Finally A "Buy" Before Earnings?
Medtronic plc remains a medical device stalwart with a robust product portfolio, but faces slow growth, high debt, and competitive pressures. I maintain a Hold rating due to a 2.76 PEG ratio, modest revenue growth, and capital deployment concerns; a further 20% price drop would improve attractiveness. Cardiac Ablation Solutions and Stealth AXIS robotic system are current growth drivers, while HUGO faces entrenched competition and limited market share potential.
